OVARIAN CANCER and US: ovarian cancer

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label ovarian cancer. Show all posts
Showing posts with label ovarian cancer. Show all posts

Saturday, January 14, 2012

Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.



 Blogger's Note: in the absence of the full paper ($$$) conclusions should be viewed with caution (eg. detailed reasons, albeit summarized in the abstract...) because....the conclusion do not make sense. 

Please post a message IF this paper is available elsewhere in open text publishing format.

 BACKGROUND:

Genetic counseling and testing is recommended for women at high but not average risk of ovarian cancer. National estimates of physician adherence to genetic counseling and testing recommendations are lacking.

METHODS:

Using a vignette-based study, we surveyed 3200 United States family physicians, general internists, and obstetrician/gynecologists and received 1878 (62%) responses. The questionnaire included an annual examination vignette asking about genetic counseling and testing. The vignette varied patient age, race, insurance status, and ovarian cancer risk. Estimates of physician adherence to genetic counseling and testing recommendations were weighted to the United States primary care physician population.

 CONCLUSION:

Physicians reported that they would refer many average-risk women and would not refer many high-risk women for genetic counseling/testing. Intervention efforts, including promotion of accurate risk assessment, are needed.

Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability



"Ovarian cancer, particularly endometrioid (cell type)adenocarcinoma, is also associated with Lynch syndrome.....Overall, 10% of tumors had abnormal MMR protein status, defined as complete immunohistochemical loss of expression of MLH1, MSH2, MSH6, and/or PMS2.....Concurrent uterine tumor was present in 5/7 patients whose ovarian tumor had abnormal MMR/MSI.......Although abnormal MMR/MSI did not carry prognostic value in this study, it did predict the involvement of the uterus by the tumor. Thus, in patients with ovarian endometrioid adenocarcinoma who undergo uterus-sparing surgery, abnormal MMR/MSI should prompt further diagnostic evaluation of the endometrium for tumor."

 

Sunday, August 28, 2011

genetics? patient safety? ovarian cancer survival? ethics? links & references - Survivors' Debate: The Past Decade in Ovarian Cancer 'CON' side of debate Sandi Pniauskas



Adobe SendNow Adobe
"CON" side of ovarian cancer debate including all aspects of care: eg. survival, access, ethics, patient safety plus reference materials
Download
File sent to you by sandi pniauskas:
2011 aug 28 2007 FINAL Revised Nov 2009 SANDI PNIAUSKAS Survivors' Debate NOVI.pdf
1.4 MB
Virus Checked
File will be available for download for 7 days.
To download the file, click on the Download button above or copy and paste this URL into your browser:
https://sendnow.acrobat.com/?i=Dj1yeKchBEAqk7*sNdpnNg
Note: Adobe SendNow may notify the sender when you download these files.
Report Abuse
Send and track large files online with confidence using Adobe SendNow (http://sendnow.adobe.com)
© 2011 Adobe Systems Incorporated. All rights reserved. 345 Park Avenue, San Jose, CA 95110 USA

Wednesday, August 24, 2011

(unpublished) Survivors' Debate: The Past Decade in Ovarian Cancer



Note: apologies for selected formatting errors

February 5th, 2008



SURVIVORS’  DEBATE:

THE  PAST  DECADE  IN  OVARIAN  CANCER


Authors:  P.J., Benivegna, C., Pniauskas

Carolyn Benivegna, Ovarian Cancer Survivor, Novi, Michigan, U.S.;
Sandi Pniauskas, Ovarian Cancer Survivor, Whitby, Ontario, Canada
corresponding author sandipn@sympatico.ca

Introduction:

Saturday, March 19, 2011

Ovarian cancer patient ‘failed by consultant’ (The Bolton News) - case of misconduct



Blogger's note: odd that the story didn't mention how the patient is doing ??

"....The panel heard that at a later consultation, the progress of the condition was again not identified and acted on, with poor notes made.
A specialist was not consulted and clinical standards of care were not met...."

Sunday, March 06, 2011

Incidence and mortality in epithelial ovarian cancer by family history of any cancer - 2011



define: sororal
Of or pertaining to a sister; Related through someone's sister

Abstract
BACKGROUND:

Practically all data on familial risk in ovarian and other cancers are based on incident cancer, whereas familiality in cancer mortality is largely unknown. If fatal forms of cancer are a highly familial subtype, then familial risk for mortality may exceed that of incidence, which is relevant for clinical decision making and counseling.

METHODS:

Ovarian cancer patients in the nationwide Swedish Family Cancer Database were classified according to fatal and nonfatal (incident) family history. Familial risks for incident and fatal ovarian cancer were calculated for offspring based on their parental or sibling family history of any cancer using standardized incidence ratios (SIRs) for incidence and standardized mortality ratios (SMRs) for mortality. Offspring without family history were referents.

RESULTS:

The database included 24,757 mothers and 8138 daughters with ovarian cancer. When a mother had ovarian cancer, the SIR for incident ovarian cancer in daughters was 2.69, and when a sister had ovarian cancer it was 3.49. The SMRs for fatal cancer by fatal cancer in probands were 3.39 and 5.80, respectively. For fatal serous cancers among siblings, the SMR was 6.16, compared with 10.01 for the endometrioid type. Ovarian cancer was associated with maternal (SIR, 1.22; SMR, 1.56) and sororal breast cancer (SIR, 1.27). Another discordant association was between ovarian and paternal prostate cancer (SIR, 1.12; SMR, 1.66).

CONCLUSIONS:

Fatal familial risks were higher for concordant ovarian, ovarian-breast, and ovarian-prostate cancers than the corresponding incident risks. This may suggest that highly fatal subtypes exist for these cancers, calling for genetic dissection. Cancer 2011

Wednesday, October 13, 2010

Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna re: Survivors' Debate (Ovarian Cancer) - repost



Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna

by Dr. Hsien-Hsien Lei
Posted September 28, 2007 in DNA Testing, DNA and Disease, Personalities with DNA

How times have changed. Cancer has come from being taboo to being a subject of debate. Even better, ever more cancer survivors are now leading the charge for better healthcare.
Two ovarian cancer survivors, Sandi Pniauskas and Carolyn Benivegna, have joined to hold the Survivors Debate: The Past Decade in Ovarian Research. Two events are scheduled for October 27 in Michigan and November 3 in Toronto. Details are available at the Survivors Debate blog.
Earlier this week, Sandi and Carolyn participated in an exclusive interview with me for Eye on DNA. Learn more about what it’s like to have ovarian cancer and these women’s experiences with genetic testing. Their very personal stories remind us of the realities of cancer.
~~~~~
Hsien Lei: What is it like to have ovarian cancer as opposed to other forms of cancer?
carolynCarolyn Benivegna: Naturally, some forms of cancer are worse than others in terms of prognosis. I have no doubt that ovarian cancer will eventually kill me. I’m a fighter, though, and I keep beating it back with the biggest sticks I can find. I have been doing this for over nine years, though they said I probably wouldn’t live two years at the time of my diagnosis. Having ovarian cancer causes me to be angry at “the system” sometimes because ovarian cancer does not get its fair share of research funding or educational/awareness efforts. This has improved over the past decade, but it’s got a long way to go.
sandiSandi Pniauskas: This is an interesting question and indeed one which is very difficult to explain. I believe that most cancer patients/family caregivers might feel the same way at the time of the initial cancer diagnosis, so I will try to explain. I think the word ‘Cancer’ is first heard and then secondarily the type of cancer. As we know from public opinion polls, the vast majority of people do not necessarily understand that cancer is not a singular disease, but many different types and each one has its own set of treatments, prognosis and profile. People often ask what type of cancer, but after that, due to the lack of awareness and education, the detailed information does not ’stick’. Improvements in this area are being made, but it is my opinion, that we must change tactics because what we have been doing is not working for the vast majority.
I knew what ovaries were of course, but, had no idea that there was a cancer called ovarian cancer. Ovaries are indeed what makes women – women and this seems like such a rather insignificant statement . That is until we realize that not having ovaries (due to surgical intervention) makes a huge impact on the way we see ourselves, as women, not to speak of the complications which result and in particular premenopausal women, such as myself, due to surgical intervention. Similar to other cancers, it is not a cancer that you can ’see’, but not having ovaries, again, is not only biologically complex but emotionally as well. I guess I might try to equate this with cancer of the gall bladder. Trying to put this into context, as an example, may be gall bladder cancer patients and this is said with the greatest of respect for those patients. Patients, cancer or not, can live without a gall bladder but it is not typically associated with an extreme physical or emotional dysfunction.
With ovarian cancer comes the surprise that you don’t need to visit ‘that’ particular aisle of the drug store anymore. It’s a small issue in the larger picture, but part of every woman’s life. In fact, I think it took me 6 months to realize that the trek down this pharma aisle was no longer required. It’s a fact, which still to this day, strikes me with a small amount of humour. The larger less humourous issue is the lack of the ability to have children and while a select few ovarian cancers are spared, this is not the norm.
As to the broader question of other forms of cancer, I would have to say that now, when the words of ovarian cancer are mentioned, it brings a reaction of “Oh, that’s a bad one’” but on the other hand, often times, the general public believe that you take out the ovaries and get on with your life, along with maybe a little chemo. It is a sense of dismissal that is concerning and that indeed exists within our patient populations to some degree today. This is very concerning and very unfortunate.
Hsien: Sandi, you had a significant history of cancer in your family. How did that influence your approach to finding treatment for your own cancer?
Sandi: In fact, the realization came only after the fact in our situation. So, allow me to explain because it is important and sends a key message for the benefit of others.
When I was first diagnosed, and as the eldest of 5 siblings, I said I was ‘happy’ for the ovarian cancer diagnosis. Why ‘happy’? I thought, in a very uninformed way, that this meant that through my diagnosis I was ‘it’ for the family – that I had taken the ‘cancer hit’ for the family and so the others would be spared. In fact, 6 months and 1 year later two younger sisters also had cancer diagnoses. We were all in our ’40’s and 3 cancer diagnoses in a time span of 2 years, a fact which is quite stunning.
Since this time, I have come to realize that not only are we not alone, but indeed, there are worse families with many more incidents/deaths of cancers. After the diagnosis of cancer of the 3rd sibling, it dawned on me that something was not right. I remembered my Mother talking about her Grandmother and ‘being in bed all of the time because she was sick from cancer”. I pursued obtaining the medical death certificate for my Great-Grandmother and indeed, she died of colo-rectal and endometrial (uterine) cancers. My Grandfather also died of a cancer but I was unable to locate that information.
As with other families, there was no one still alive to ask for further information and this made it more challenging, but not insurmountable. The unfortunate part of all of this, in hindsight, is that it did not have to happen but it wasn’t necessarily the fault of anyone person, just the set of circumstances and timing. Unlike our situation, however, if there is any cancer diagnosis in the family it would be important to explore the family history right at the time of the initial diagnosis rather than letting it happen, so to speak. It might have saved my younger sister from her death, not to mention the suffering.
We are part of the genetic syndrome which is called the Lynch Syndrome and sometimes it is known as the ‘family cancer’ because of the wide range of cancers experienced in these families, ovarian cancer of which is one. Since I had already had my treatments, approach to treatment is an after-the-fact question. However, I had encouraged my younger sister to maintain a heightened surveillance program as her risk factors were the most similar to mine. At the time and before her diagnosis, I did not understand the connection and the risk for other cancers.
Would a heightened awareness and surveillance program have influenced her outcome? The answer at the very least is quite possibly.

teal ribbonHsien: Carolyn, do you also have a family history of cancer? How did this knowledge affect you?
Carolyn: Yes, my maternal grandmother died of breast cancer, my maternal grandfather died of stomach cancer, and my maternal aunt died of ovarian cancer. There was also some breast cancer on my father’s side of the family (two of his sisters). That’s why I was always conscientious about breast cancer screening, never dreaming that I was a candidate for ovarian cancer (having had my ovaries removed many years before my ovca diagnosis). After I was dx. with ovca, I insisted on genetic testing and was found to be BRCA-1 positive. Since then 12 other members of my family have been tested for that specific genetic mutation, and they are ALL positive.
The knowledge of the genetic mutation affected me by moving me into action to educate my family members about the genetic predisposition to the various cancers in the BRCA-1 mutation. It has also influenced my decisions on which treatments to take.
Hsien: How did you feel before, during, and after genetic testing (prior to receiving your results)?
Carolyn: I think I was generally numb before my genetic testing. I knew I had to do it, and I did it. I had been diagnosed, had surgery, and had two of six scheduled chemo treatments when I decided on genetic testing.
When I was found to be BRCA-1 positive, I was disappointed because it meant that my children were at risk due to something I had inadvertently passed on to them. Though I know I shouldn’t feel guilty about this, I can’t help feeling responsible for passing on something to them that could cause them a lot of pain and illness sometime in the future.
I’m glad I was tested, however, because I believe that knowledge gives us the power to make enlightened decisions about our healthcare. Prior to my diagnosis, I was not knowledgeable about ovarian cancer or genetic mutations and, consequently, was diagnosed at Stage IIIC Primary Peritoneal Cancer.
Sandi: I initiated the genetic testing for both the BRCA 1/2 and the Lynch Syndrome after our diagnoses. The rationale for the BRCA testing was due to unknown cancer types in our family, as well as a female first cousin, who was diagnosed with an early-age breast cancer. At this point, for me, the question was not what, but what to do with the information.
From a strictly scientific perspective and to bring research forward, I knew that genetic testing might one day bring a resolution to many of the unanswered questions and for the benefit of our future generations. So, I tried to look at this very clinically. Because I pursued the genetic testing after completing my treatments of surgery, chemotherapy and radiation, I had the benefit of time to reflect on the emotional issues. I often times try to convey to people that if we can, and it is not always possible, we need to put that emotional aspect in ‘a little box’. This is what I was able to do and this is strictly an individual response.
Not having had children also was of benefit because there was no burden of passing along those genes, which in my own personal set of circumstances made the genetic testing a much easier decision. If I had had children, the decision would have become much more complicated.
At the initial time of pursuing the genetic testing, I didn’t believe that waiting for the test results would be an issue. Understanding that while genetic testing in Canada is covered under our universal healthcare system, the results are not received in a timely manner. The results of the BRCA testing took 4 months and the results of the Lynch Syndrome testing took approximately a year. I kept myself very busy with ovarian cancer advocacy issues and participation in our international online community which is an easy way to say, I kept myself busy. However, not long after, I told the genetic counselor that while I thought waiting for the test results was not an issue, indeed, it was.
The BRCA results were negative which I anticipated. The Lynch Syndrome testing was ‘inconclusive’ meaning they were unable to locate anyone of the known genes. It is my belief that the only truly significant result is a positive result and while this stuns many people, to me a positive result means that there is some form of certainty and as a result there is a plan of action. An inconclusive result does not answer the question. Having said this, without a conclusive result, meaning a positive result, we are still faced with the reality of the family history and are waiting for science to catch up with us.
I do have to say that I am very encourage by new and recent research findings and while this does not necessarily, depending on the genetic syndrome, at this time, translate into day-to-day care, it will. After receiving the results, I am a firm advocate for awareness both within the healthcare professional communities and patient communities for the benefit of those who might be at risk for any familial link/cancer predisposition through a known genetic syndrome. It is important also for all cancer patients to understand that there are quite a number of different syndromes, so appropriate genetic counselling is crucial.
Hsien: After receiving the results of your genetic tests, how did you feel? How did the results influence your life choices?
Sandi: At this time, there are few options available for my future life choices. Surveillance and screening are available for only 2 of the cancers for which I am at risk. Fortunately, the highest risk for me at this point is colo-rectal cancer and there is screening available through colonoscopies. For those other cancers of which I am risk, there is no screening. However, we have taken care of endometrial and ovarian cancer risks due to my onset of ovarian cancer. While I am at a lesser risk for stomach and pancreatic cancers, I am hoping that those are not the ones which I will die from. At the same time, there continues to be the risk of a late/new ovarian cancer although small. Risk is all relative and risk is only low if it is not you – that’s the mind-game in all honesty.
Hsien: What do you think will be the hottest topics of the Survivors Debate? You specifically mention genetics and access to care and communications. How do your two viewpoints differ from one another? What do you hope people will do after attending the Debate?
Carolyn: I think one of the hottest topics will be “Access to Care.” This is a big issue in the U.S. right now and is a problem here and throughout the world. Sandi and I actually agree on many subjects. For the sake of the debate, we are taking opposing viewpoints on all the issues so that we can present diametrically opposite viewpoints, as a debate should!
I (personally) hope the debate will help create an environment where survivors will be included more in the dialog and decision-making processes as they pertain to cancer. I hope the controversy spurred by the debates will accelerate forums of this nature, resulting in increased research, treatment, and communication that includes survivors as the very core.
Sandi: One of the most important features of the Survivors’ Debate programs is that it allows, without bias or judgment, a public forum for people to express themselves through dialogue and indeed challenge the issues of what is not working. We know what is working, but we need to address what is not – publicly.
Personally, I am tired of doing the same-old, same-old. What always worries me is that many patients feel that by speaking up and out that this will impact their care. We must and need to change this sense of, in some cases a lack of entitlement, and it take a great deal of morale fortitude to do so. We encourage healthcare providers to attend en masse and also speak openly about their own issues. We want you to sit side by side with your patients – the human compassion and understanding which we will all take away with us will be the greatest and most successful and lasting result. It is also hoped that with public debate we can apply pressure for change. I have the belief and know that we can, but the question is will we?
There is a lot of anger amongst all of us, most of which is related to system failures. Today, we still have not been able to address the issues of the Patients voices in any effective way. Patients for the most part have the highest regard for their professional caregivers and want to have these dialogues. Fear of the unknown holds us back but it is decidedly less of a fear than the cancer itself, in my view. At the moment, other people are speaking for cancer patients and their families and we are at the point where the information is not being translated effectively.
The dichotomies in the medical literature attest to this where patients/family caregivers and medical staff do not have the same opinions on what is important. In fact, many healthcare professionals’ stories also note these issues. This is not so much of a criticism but a recognition of where we need to go. It is my profound expectation and hope that through these public forums we can bridge this gap. The debate forums allow us to take that much needed step forward, translating patients intellect and sense of responsibility and bring with it a public voice as opposed to a non-cancer voices in healthcare decision-making. If we do not do this, changes will occur which will not be effective in any meaningful way to those for whom we serve – the patients. This in fact, will be the change and from my perspective of mutual benefit to all.
On a personal level, I have lost not only family but most of the friends whom I first came into contact with when newly diagnosed. I simply cannot accept the degree of suffering which I experience each day, through others, without at least trying to take yes, a controversial but important step forward. These forums are not without controversy but we must put aside the issues which consistently get in the way of moving forward. I cannot think of a better or more humane way in which to do so.
Carolyn and I agree, as Carolyn mentions, on most issues. Most importantly ovarian cancer is a global issue and while some of the access to care are points of technical issues, the reality is that ovarian cancer to Carolyn and ovarian cancer to me, are the same. We both think this is extremely exciting that today patients are or can be the experts in their own cancers. If by chance, our information is lacking, then we want to know and we cannot underestimate how we truly believe this. An oncologist once told me that a little information is a dangerous thing. After initially being significantly annoyed, I decided he/she was right. These are our efforts to profile and dialogue what is not understood about the ‘average’ cancer patient but more important what is important. The learning curve has been steep, but it can be done.
The Debates are the mechanism to do so.
Thank you so much for allowing us to present our views, concerns and hopes for the future.
~~~~~
Bravo, Carolyn and Sandi! Thank you for sharing your stories and thoughts with us. There are many cancer survivors who will undoubtedly be inspired by your proactive determination.

Saturday, July 31, 2010

Press Release: Canada's Leading Ovarian Cancer "Patient" Advocate Speaks at Sask Conference






 

OCATS

Ovarian Cancer Awareness & Treatment in Saskatchewan
A SUPPORT & ACTION GROUP FOR ANYONE AFFECTED BY GYNECOLOGIC CANCERS

M E D I A   R E L E A S E


CANADA’S LEADING OVARIAN CANCER “PATIENT” ADVOCATE SPEAKS AT SASK CONFERENCE

For Immediate Release
REGINA, July 26, 2010  - Conference Co-Chairs Scott Livingstone, CEO Sask Cancer Agency and Darlene Gray, President, OCATS, in partnership with CNT Management Group, invite survivors, support people and the medical community to the first ever Gynecologic Cancer Conference, Strategies for Survival on September 24, 2010 at the Regina Inn.  Early Bird registration fees available until the end of July for this important event featuring some of the province’s most knowledgeable specialists in female reproductive cancers.  Experts will address clinical study trials for new drug therapies, managing cancer recurrence, the emotional aspects of cancer diagnoses, identifying families with hereditary risks, alternative and complimentary therapies available and the roles of our nurses, general practitioners, and pharmacists in cancer care delivery.

A conference highlight will be a presentation by Canada’s leading ovarian cancer “patient” advocate, Sandi Pniauskas.  Other experts presenting at the conference include the following.

Dr. Christopher Giede, Gynecologic Oncologist at the Royal University Hospital, Saskatoon and the team leader of Saskatchewan gynecologic oncology team of female reproductive cancer specialists.
Dr. Muhammad Salim, Medical Oncologist at the Allan Blair Cancer Centre, Regina and the specialist of all our Clinical Study Trials. 
Dr. Vicki Holmes, Medical Director of the Women’s Mid-Life Health Centre in Saskatoon. Dr. Holmes developed the concept of this centre and is the resident physician at the centre.
Rosalee Longmoore, RN, a Registered Nurse for 34 years with a wide range of experience on all Saskatchewan medical nursing issues.
Andrew Gilbertson, Pharmacist and owner of Hill Avenue Drugs, Regina, Regina’s first and currently only pharmacy that specializes in compounding custom prescription medications.
Dr. Heather Fox, Naturopath, a health specialist with over 30 years experienced and a registered doctor of Natural Medicine through the Examining Board of Natural Medicine Practitioners, Canada.
Monica Milas, Personal Growth and Healing Services Counsellor and Therapist.
Wendy Stoeber, Genetic Counsellor at the Division of Medical Genetics, Royal University Hospital, Saskatoon.
And a member of the Gynecologic Oncology Program Working Group, Scott Livingstone, the new CEO of the Sask Cancer Agency, will speak about Saskatchewan’s new Gynecologic Oncology Program.

The conference will include an exhibit hall marketplace and be followed by the OCATS Annual Benefit Gala and Silent Auction featuring Jack Semple and presentation of the OCATS 2010 Catleya Award of Collaboration & Vision.  Conference on-line registration at  http://guest.cvent.com/EVENTS/Info/Summary.aspx?e=ce9c4a0f-157e-4a42-ab49-0f19dae902e3. A group guestroom rate is available at the Regina Inn by asking for the OCATS event.  Discounted conference fees available for OCATS members and all students.  For more information please contact Darlene at 306-775-1848 or CNT Management Group Claire Bélanger-Parker [claire.belanger-parker@cntgrp.ca].

For more info contact Darlene Gray at OCATS at 306-775-1848, cell 529-3199 or darlenegray@sasktel.netdarlenegray@sasktel.net
# # #

Thursday, July 29, 2010

abstract: Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer (meta-analysis)



CONCLUSIONS

Although individual studies have not yet convincingly shown a survival advantage with maintenance chemotherapy in OC, this meta-analysis demonstrates that continued chemotherapy after completion of primary therapy for OC improves PFS and OS. Benefits are greatest in patients with advanced stage OC who reach complete clinical or pathologic response after primary therapy.

Tuesday, April 27, 2010

Saskatchewan Science - National Biotech Competition awards - student award/ovarian cancer



"Brian, a Grade 11 student at John F. Ross Collegiate Vocational Institute, won the 2nd place prize for his project that found a green tea extract offered a potential new treatment for ovarian cancer."

Saturday, April 24, 2010

CHUM (Montreal) turns cancer patients away



"The crisis at Notre Dame Hospital, a renowned cancer treatment centre, has reached such acute proportions that hospital officials are sending letters to women diagnosed with gynecological cancer to seek treatment elsewhere – in hospitals in Quebec City and Trois Rivières....."

"In fit of anger, (Dr.) Sauthier penned an open letter to his colleagues accusing the Quebec Health Department, the Quebec College of Physicians and his hospital of ignoring best practices in favour of balancing the books.

"Ovarian cancer survivor Suzanne Poulet read Sauthier’s letter aloud after Health Minister Yves Bolduc lauded his department’s successes inbreast and colon cancer screening programs as well as anti-smoking legislation. “What about problems operating on women with gynecological cancer?” Poulet demanded. Such delays are “intolerable” and “unacceptable,” Bolduc responded. “It’s an emergency and we are in the process of fixing it.”

Read more: http://www.montrealgazette.com/health/CHUM+turms+cancer+patients+away/2945070/story.html#ixzz0lzEiOwCF

Tuesday, April 13, 2010

Facebook | Darlene Gray: Sask Minister of Health Questioned in Leg Assembly Over the Closure of Regina Gyne Onc Office



Sask Minister of Health Questioned in Leg Assembly Over the Closure of Regina Gyne Onc Office
THIRD SESSION - TWENTY-SIXTH LEGISLATURE
of the
Legislative Assembly of Saskatchewan
N.S. VOL. 52 NO. 42A MONDAY, APRIL 12, 2010, 1:30 p.m.
LEGISLATIVE ASSEMBLY OF SASKATCHEWAN 4697 April 12, 2010
April 12, 2010 Saskatchewan Hansard 4705

ROUTINE PROCEEDINGS
INTRODUCTION OF GUESTS

Ms. Junor: — Mr. Speaker, I too on behalf of the opposition want to welcome the members from the Red Hat Society, all the women that have come today. From what I know about this group, not only are they very visible because of their hats — and it’s unfortunate that the member didn’t wear hers; that would have been entertaining — I understand that these women are extremely enthusiastic and they have a lot of fun. That’s what I always hear, that you have a lot of fun. Look at all the hats nodding. So I too would like to welcome all the women here today to the legislature.

While I’m on my feet, Mr. Speaker, I want to introduce others who are in the gallery. On the very top row is Darlene Gray, the director of OCATS, the Ovarian Cancer Awareness and Treatment in Saskatchewan, and Elan Morgan board member. Wave? And sitting beside Elan are Joan and Harvey Schneider, also board members. I just want to say about Joan before I sit down and welcome them, Joan was the executive secretary to the president of SUN [Saskatchewan Union of Nurses] when that was me. So I’m very happy to see Joan here today and welcome them all to the Assembly.

QUESTION PERIOD
Gynecologic Oncologists

Ms. Junor: — Mr. Speaker, for two years the minister has ignored the pleas of women with ovarian cancer and gyne-oncologists to address substandard working conditions in southern Saskatchewan. As a result, Dr. Brydon, one of only two gyne-oncologists practising in southern Saskatchewan, has closed her practice because she is burned out. To quote Dr. Brydon, “Physically and emotionally, I can’t cope any more.”
Mr. Speaker, the minister’s incompetence and failure to address the substandard working conditions of gyne-oncologists in Regina is putting at risk the lives of women with ovarian cancer. Why?

The Speaker: — I recognize the Minister of Health.
Hon. Mr. McMorris: — Thank you, Mr. Speaker. First of all, Mr. Speaker, on behalf of the government, we want to thank Dr. Brydon for all the work that she has done in southern Saskatchewan. These people are very specialized doctors. They are, Mr. Speaker, gynecology oncologists, which is a very specialized area. We have had four in our province, Mr. Speaker. Dr. Brydon is closing her practice to move on to other options. The health region, the health region as well as the government, is working hard to ensure that that position will be filled, Mr. Speaker.
But what I will say is that in the last two and a half years of our government, we have done more to recruit physicians into this province compared to the 16 years. And especially when you look at the front page of the Leader-Post, from 2001 to 2006 the net out-migration of health care workers in Saskatchewan was 1,160 health care workers out, Mr. Speaker. In our first two and a half years, we have attracted 164 more physicians to our province than under that government, Mr. Speaker.

The Speaker: — I recognize the member from Saskatoon Eastview.
Ms. Junor: — Mr. Speaker, that tired rhetoric is no consolation to women who have ovarian cancer. Mr. Speaker, in every other jurisdiction, including Saskatoon, gyne-oncologists work in a hospital setting with the proper support around them — not so in Regina where the specialists have to find their own office space and work without the support of a nurse.

Mr. Speaker, to the minister: is he going to provide immediate office space and examining room space in the Regina General Hospital along with the proper nursing support, or is he going to continue to ignore the issue until the second gyne-oncologist closes her practice?

The Speaker: — I recognize the Minister of Health.
Hon. Mr. McMorris: — Mr. Speaker, we have a gynecological oncology program working group that was established, Mr. Speaker, under our government. This working group has patient support, is represented through patient support groups. It also has a gynecology oncologist, the four that were in the province, working on this group as well as the health authorities of Regina Qu’Appelle, Saskatoon, and the Saskatchewan Cancer Agency to deal with this issue to have an ongoing program.

Mr. Speaker, the ministry officials have informed me that progress is being steadily made, Mr. Speaker. And yes, there are going to be decisions made by physicians to step aside. But, Mr. Speaker, we’re going in the right direction. It isn’t the working of that group . . .
[Interjections]

The Speaker: — Order. Order. I’d ask the opposition members to give the minister the same opportunity to respond as the government gave the member to ask the question. I recognize the minister.
Hon. Mr. McMorris: — Mr. Speaker, it isn’t the working of that group that would get into the micromanagement of what happens within a health region or the Cancer Agency. That is the auspices of the Cancer Agency or the regional health authority in their particular area, Mr. Speaker.

The Speaker: — I recognize the member from Saskatoon Eastview.
Ms. Junor: — Mr. Speaker, this is clearly a lack of leadership. The working group has been ongoing for over two years. They’re going to just keep spinning their wheels unless the minister says, do this. The minister’s incompetence and failure to address the problems means there’s now only one gyne-oncologist looking after all of southern Saskatchewan women. This will put additional pressures on the remaining gyne-oncologist and potentially will increase the wait time for women who are waiting for even an initial diagnosis.

My question to the minister is this: will the Sask Party government be forced to send women out of the province for diagnosis and treatment because of their incompetence and failure?

The Speaker: — I recognize the Minister of Health.
Hon. Mr. McMorris: — As I had mentioned earlier that the health region, the Saskatchewan Cancer Agency, the Regina Qu’Appelle Health Region will be working hard in the next . . . in the past but as we move forward over the next month or so to attract another gyne-oncologist into the province. I am very proud of our government having set up a physician recruitment agency that will deal with this very issue, these very issues, Mr. Speaker.

Unfortunately that hadn’t been done for many, many years — never even contemplated under the former government when we saw hundreds and hundreds of doctors leaving this province, Mr. Speaker. In the last two and a half years, we’ve seen more doctors come to the province than leave — an increase of about 164. There is more work to do. That’s why we set up a recruitment agency, Mr. Speaker. And that’s why we’ve also increased the number of training seats in the College of Medicine and the number of residency positions, up to 108 residency positions in the province, Mr. Speaker, that will bode this province very well into the future.

The Speaker: — I recognize the member from Saskatoon Eastview.
Ms. Junor: — Mr. Speaker, ducking and weaving, I mean there is no answer in the minister’s rhetoric. And Dr. Brydon’s leaving her practice now because the province will not set up a gyne-cancer unit in Regina. This unit would allow women to be diagnosed, treated, and receive follow-up care in one place. To quote Dr. Brydon:
I actually don’t think that the way the system is structured in this province at this time allows anybody to do the job that needs to be done properly and that is because we do not have a gynecologic women’s cancer unit the way all other provinces do.
Mr. Speaker, to the minister: is the minister going to establish a gyne women’s cancer unit in the province now, or is he going to wait and wait and wait, and talk and talk, and talk and continue to risk the lives of women with ovarian cancer?

The Speaker: — I recognize the Minister of Health.
Hon. Mr. McMorris: — Mr. Speaker, we know and understand the very importance of this issue, Mr. Speaker. That’s why we set up a working group that has patient representative groups on it, that has the oncologists on it, that has the Cancer Agency, that has the health regions, to look at how to best manage this project, Mr. Speaker. There has been progress made, absolutely. But it’s interesting that they would stand and criticize the way the program and the way the health system is being run, when they have been in government for 16 years prior, setting up the very program they’re criticizing now, Mr. Speaker.
Mr. Speaker, we’re looking at how we can improve this program as we move forward. We’re looking at how we can have the proper complement of gyne-oncologists within the province, Mr. Speaker, because we know that it is a very important issue, and we’re working to improve the health of women in our province, Mr. Speaker.